Materias dentro de su búsqueda.
Mostrando 4,301 - 4,320 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.26s Limitar resultados
  1. 4301
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme
  2. 4302
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
  3. 4303
    “…CONCLUSIONS: These findings support palbociclib plus endocrine therapy as standard of care for HR+ /HER2− ABC patients, regardless of baseline TFI/DFI or intrinsic molecular subtype, including patients with bone-only disease. TRIAL REGISTRATION: Pfizer (clinicaltrials.gov:NCT01740427, NCT01942135).…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
  4. 4304
    “…(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
  5. 4305
    “…McGuiness, MA, MS, GSK (Research Grant or Support)Pfizer (Shareholder) Lisa I. Glasser, MD, GSK (Employee, Shareholder) Kainan Sun, MS, PhD, GSK (Research Grant or Support) Philip O. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States
  6. 4306
    “…Pelton, MD, Merck vaccine (Consultant, Grant/Research Support)Pfizer (Consultant, Grant/Research Support)Sanofi Pasteur (Consultant, Other Financial or Material Support, DSMB)Seqirus Vaccine Ltd. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
  7. 4307
    “…Kaplan, MD, Allergan (Research Grant or Support)Pfizer (Grant/Research Support) Jonathon C. McNeil, MD, Allergan (Research Grant or Support, Allergan provided ceftaroline powder for use in studies described in this abstract)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1367. Reduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s HospitalReduced Ceftaroline Susceptibility Among Invasive MRSA Isolates at a Tertiary Children’s Hospital
  8. 4308
    “…DISCLOSURES: Jessica Howard-Anderson, MD, MSc, Antibacterial Resistance Leadership Group (ARLG) (Other Financial or Material Support, The ARLG fellowship provides salary support for ID fellowship and mentored research training) Nadine Rouphael, MD, Lilly (Grant/Research Support)Merck (Grant/Research Support)Pfizer (Grant/Research Support)Quidel (Grant/Research Support)Sanofi Pasteur (Grant/Research Support)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    411. Application of a SARS-CoV-2-specific serologic assay for translational research and surveillance
  9. 4309
    “…Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor) Roger Echols, MD, Shionogi Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1252. In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies
  10. 4310
    “…Marshall, MD, GlaxoSmithKline (Consultant, Scientific Research Study Investigator)Merck (Consultant, Scientific Research Study Investigator)Pfizer (Consultant, Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Grant/Research Support, Scientific Research Study Investigator, Honorarium for conference lecture)Seqirus (Consultant, Scientific Research Study Investigator) Craig S. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1386. Current Estimates of the Impact of Routine Childhood Immunizations in Reducing Vaccine-Preventable Diseases in the United States
  11. 4311
    “…(Grant/Research Support, Speaker’s Bureau)MSD Japan (Grant/Research Support, Speaker’s Bureau)Pfizer Japan Inc. (Grant/Research Support)Sumitomo Dainippon Pharma Co., Ltd (Grant/Research Support, Speaker’s Bureau)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1205. Protectin D1 Induced by Clostridium butyricum MIYAIRI 588 Has an Anti-inflammatory Effects on Antibiotic-induced Intestinal Disorder
  12. 4312
    “…(Grant/Research Support, Speaker’s Bureau)MSD Japan (Grant/Research Support, Speaker’s Bureau)Pfizer Japan Inc. (Grant/Research Support)Sumitomo Dainippon Pharma Co., Ltd (Grant/Research Support, Speaker’s Bureau)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    878. Antimicrobial Susceptibility of Pathogens Isolated from Surgical Site Infections in Japan: Comparison of Data from Nationwide Surveillance Studies Conducted in 2010, 2014–2015 and 2018-2019
  13. 4313
    “…Marshall, MD, GlaxoSmithKline (Consultant, Scientific Research Study Investigator)Merck (Consultant, Scientific Research Study Investigator)Pfizer (Consultant, Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Grant/Research Support, Scientific Research Study Investigator, Honorarium for conference lecture)Seqirus (Consultant, Scientific Research Study Investigator)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1399. Parental Perceptions of the Childhood Vaccination Schedule and Combination Vaccines in the United States (US)
  14. 4314
    “…DISCLOSURES: Luis Ostrosky-Zeichner, MD, Amplyx (Scientific Research Study Investigator)Astellas (Consultant, Scientific Research Study Investigator, Other Financial or Material Support, Non-branded educational speaking)Biotoscana (Consultant, Other Financial or Material Support, Non-branded educational speaking)Cidara (Consultant, Scientific Research Study Investigator)F2G (Consultant)Gilead (Consultant)Mayne (Consultant)Octapharma (Consultant)Pfizer (Other Financial or Material Support, Non-branded educational speaking)Scynexis (Consultant, Grant/Research Support, Scientific Research Study Investigator)Stendhal (Consultant)Viracor (Consultant)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    860. A Proposed Standard for Hospital Bioaerosol Monitoring in Avoiding Nosocomial Mould Infections
  15. 4315
    “…DISCLOSURES: Allison McGeer, MD, FRCPC, GlaxoSmithKline (Advisor or Review Panel member, Research Grant or Support)Merck (Advisor or Review Panel member, Research Grant or Support)Pfizer (Research Grant or Support)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    837. Contamination of Hospital Drains by Carbapenemase-Producing Enterobacterales (CPE) in Ontario, Canada
  16. 4316
    “…Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor) Roger Echols, MD, Shionogi Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
  17. 4317
    “…(Research Grant or Support)Pfizer Pharmaceuticals (Research Grant or Support)Shionogi, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    621. Reporting Behaviors and Perceptions Towards the National Healthcare Safety Network Antimicrobial Use (AU) and Antimicrobial Resistance (AR) Options
  18. 4318
    “…DISCLOSURES: David Paterson, Accelerate (Speaker’s Bureau)BioMerieux (Speaker’s Bureau)BioMerieux (Advisor or Review Panel member)Entasis (Advisor or Review Panel member)Merck (Advisor or Review Panel member)Merck (Grant/Research Support)Merck (Speaker’s Bureau)Pfizer (Speaker’s Bureau)Shionogi & Co., Ltd. (Grant/Research Support)VenatoRx (Advisor or Review Panel member) Masahiro Kinoshita, MPharm, Shionogi & Co., Ltd. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1285. Outcomes in Patients with Gram-Negative Bacteremia from Phase 2 and Phase 3 Clinical Trials of Cefiderocol, a Novel Siderophore Cephalosporin
  19. 4319
    “…Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    164. in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018
  20. 4320
    “…Alden, MPH, CDC (Grant/Research Support) Lee Harrison, MD, Dynavax (Consultant)GSK (Consultant)Merck (Consultant)OMVax (Consultant)Pfizer (Consultant)Sanofi Pasteur (Consultant)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    85. Characterization of Group B streptococcus Strains with Reduced Susceptibility to Beta-lactam Antibiotics, Active Bacterial Core Surveillance, 1998–2017
Herramientas de búsqueda: RSS